Introduction
The physiological functions of three polypeptides that form the NPY peptide family, neuropeptide Y (NPY) 1 and peptide YY (PYY), 2 and pancreatic polypeptide (PP), 3 antagonists may have potential as orexigenic agents to treat anorexia. [6] [7] [8] [9] In developing such ligands, truncated peptide analogues are becoming increasingly popular. For example, [Nle 30 ]hPP [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] and [Leu 34 ]pNPY [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] were found to be Y 4 R selective partial agonists, 10 and a nonapeptide based on the C-terminal fragment of NPY, Ile-Asn-Pro-Ile-Tyr-Arg-Leu-Arg- [28] [29] [30] [31] [32] [33] [34] [35] [36] ], also known as 1229U91, showed enhanced potency at both receptor subtypes but is in particular the most potent known Y 1 R antagonist. [13] [14] [15] [16] [17] Another of several highly potent Y receptor ligands based upon dimeric C-terminal sequences is D/L-2,7-diaminooctanedioyl-bis(YRLRY-NH 2 ), 1 (BVD-74D) 18 ( Figure 1 ).
This peptide exhibited comparable Y 4 R affinity with the native hPP (K i = 0.05 nM vs. 0.08 nM) and showed 150-fold selectivity for Y 4 R over Y 1 R, and negligible affinity to Y 2 R and Y 5 R. In fasted rat subjects, 1 showed equally potent inhibitory effects on food intake as the endogenous PP. 18 A later study also reported that 1 significantly reduced food intake, water 4 intake and weight gain in mice fed with normal and high-fat diet. 19 However, the reported compound is, in fact, a mixture of diastereomers composed of the (2S,7S)-and (2R,7R)-diaminooctanedioyl-containing stereoisomers, 18 and they are inseparable by RP-HPLC.
Therefore it was unclear which stereoisomer contributed to the in vitro and in vivo pharmacological activity. We aimed to resolve this issue, and set a platform for the broader investigation of Y 4 R pharmacology by the synthesis of optically pure stereoisomers of 1 and related analogues that probe the role of the bridging group and the role of the dimeric structure in facilitating high affinity. We hereby present our work on synthesis of a series of optically pure analogues of (S,S)-1 and (R,R)-1 along with their fluorescently labelled variants. We developed methodology for preparing the dimeric peptides utilising Grubbs metathesis, either in the synthesis of optically pure 2,7-diaminosuberic acid building blocks or the on resin metathesis of monomeric precursor peptides. [20] [21] [22] Those peptide analogues were analysed using cell based Y 4 R competition binding assays and β-arrestin recruitment assays to identify the (R,R)-diastereomers as the high affinity constituent of 1 and the corresponding fluorescent analogues.
Results and Discussion
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The main challenge in developing a convenient and robust strategy for synthesising optically pure dimeric 1 analogues was to identify an optimal condition for metathesis reactions. Two different approaches were attempted. The first approach involved pre-synthesis of the 2,7-diaminosuberic acid unit then bis-coupling to the linear peptidyl-resin, while the second involved a solid phase cross-metathesis between two completed linear N-terminal allylglycine containing peptides.
Synthesis of (S,S)-1 and (R,R)-1
The synthesis of (2S,7S)-N,N-di-Boc-diaminosuberic acid 23 (2S,7S)-5 via metathesis was achieved by adapting the methods of Nolen et al. 24 and Ward et al. 25 (Scheme 1) The (S)-NBoc-allylglycine methyl ester (2) was treated with Grubbs catalyst 2 nd generation in refluxing DCM overnight to obtain the desired alkene 3 in 95% yield. The intermediate 3 was then hydrogenated in presence of 10% Pd/C, which gave 4 almost quantitatively. Finally, the desired product (2S,7S)-5 was generated by ester hydrolysis. Spectroscopic data for (2S,7S)-5
were consistent with that previously reported, 23 including the determined (-) optical rotation in DMF. 26 Experimental details are provided in Supporting Information. To further confirm the chiral integrity of the products, a chiral HPLC method was developed that showed that preparation of (2S,7S)-5 and (2R,7R)-5 was not accompanied by significant racemization either to each other or to the meso (2R,7S)-5 29 in these syntheses (see Supporting Information).
Having the protected building blocks in hand, dimeric peptide analogues (S,S)-1 and (R,R)-1 were prepared by conventional solid phase peptide synthesis (Scheme 3). After constructing the linear peptide chain on Rink amide resin, the coupling was carried out using 0. Reagent K, RT, 3 h.
As an alternative approach, the synthesis of dimeric peptides was achieved by solid phase cross-metathesis of the corresponding resin-bound protected allylglycine containing peptides.
(Scheme 4) The monomeric peptide chain containing either L-or D-allylglycine was first assembled following the standard Fmoc-based solid phase synthesis strategy, where the Nterminal Fmoc group was retained. The peptidyl-resin was then subject to cross-metathesis by treating with Grubbs catalyst 2 nd generation under deoxygenated conditions and microwave heating in presence of LiCl as a chaotropic salt. 21 Fmoc deprotection followed by cleavage yielded the alkenyl peptides, (S,S)-9 and (R,R)-9.
The synthesis of (R,R)-1 was also achieved by hydrogenation of (R,R)-9 in presence of 10% Pd/C in EtOAc (Scheme 4). While successful and operationally straightforward, the yield and purity of the crude peptide product was not as good as the same peptide made from presynthesised diaminosuberic acids as described above. 21 
Synthesis of homo-and hetero-dimeric methyl esters of (S,S)-1
Having established efficient strategies for preparation of dimeric analogues with specified stereo-configuration, we investigated the role of the C-terminal amides in Y 4 R interaction by replacing them as mono-or di-methyl esters. Our strategy was to utilise side-chain anchoring to the resin to allow manipulation of the terminal carboxylate. Peptide anchoring to resin via the side-chain of tyrosine esters has been described on both benzyl-type resins 30 and 2-chlorotrityl chloride resin. 31 We first prepared the free phenolic tyrosine derivatives, Fmoc-Tyr-OMe (10) 32 and FmocTyr amide (11) 33 (see Supporting Information). The di-methyl ester (S,S)-12 was achieved by coupling 10 to 2-chlorotrityl chloride resin via the phenol group. 31 The remainder of the peptide sequence was assembled as described above with final coupling of (2S,7S)-5 and standard acidolytic cleavage (Scheme 5).
To synthesise the heterodimeric mono-methyl ester (S,S)-13, 10 and 11 were anchored simultaneously to 2-chlorotrityl chloride resin as a 1:1 mixture. Standard SPPS was continued as described above and final coupling of (2S,7S) and rhodamine B (RhB).
Scheme 6:
Example of fluorophore conjugation of (S,S)-1. Reagents and condition: sCy5 or RhB (0.7 eq.), PyClock, DIPEA in DMF, RT, overnight.
In summary, we have successfully developed unambiguous synthetic routes to prepare optically pure 1 and analogues through both solution and solid phase alkene metathesis reactions. Mono-labelled fluorescent analogues were conveniently prepared by standard solution phase coupling using limited molar equivalents of fluorophores. Utilising these strategies, 11 dimeric analogues were prepared and their analytical data are summarised in Table 1 . Figure 3) . 36, 37 The endogenous reference ligand, human PP, showed a. Sub = 2,7-diaminosuberoyl linkage; ∆sub = 2,7-diaminooctene-4-dioyl linkage b. Derived from competition binding assays using 100 nM 17 as the fluorescent ligand.
c. From Y 4 R-β-arrestin2 recruitment assays.
d. In the absence of significant agonist activity, the effect at 1 µM peptide is reported. N.D.
= not determined
The remaining analogues examined here have not been previously described (Table 2 ). In the alkenyl dimer series, a preference for the (R,R)-9 was again observed compared to the (S,S)-diastereomer, but overall these compounds showed 2-to 3-fold lower affinity for Y 4 R than 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 15 ligand images were acquired on an IX Ultra platereader. The panels show 400×400 regions of interest from the 1000×1000 pixel original plate images; scale bar 50 µm. B. Specific binding of 17 was quantified and normalised using granularity analysis as described in the methods, to obtain competition curves for peptide analogues synthesised in the current study. Graphs show pooled competition data (n = 5), from which the pIC 50 values in Table 2 The functional Y 4 R agonism produced by the peptides was analysed using a β-arrestin2 recruitment assay to detect Y 4 R activation (Figure 4) , as previously described. 39, 40 One advantage of this assay is its limited receptor reserve, which improves correspondence between agonist potency (as EC 50 , the concentration of agonist that produces 50% of its maximal response) and underlying functional receptor affinities, and also the likelihood that differences in agonist intrinsic efficacy are revealed through changes in relative maximum response (R max ). 41 Thus the reference agonist human PP stimulated β-arrestin2 association with an EC 50 value (2.6 nM) very similar to its derived pIC 50 in the whole cell Y 4 R binding experiments.
Compared to PP, all the peptides were partial agonists in the Y 4 R-arrestin recruitment assays, with typical R max values 44-62% of that of PP ( Table 2 ). The order of potency broadly reflected binding data in that (i) (R,R)-1 (EC 50 = 4.6 nM) was 20-fold more potent than the (S,S)-1, (Figure 4A ), (ii) the alkenyl derivatives (R,R)-9 and (S,S)-9 were less potent overall than the dimers with saturated linkages ( Figure 4B ) and (iii) replacement of one or both C- Figure 4B ).
The functional assay enabled assessment of both RhB-and sCy5-labelled analogues as Y 4 R agonists. In general, maximum responses to rhodamine analogues were reduced compared to the respective parent compounds, with compound (S,S)-15 (RhB derivative of (S,S)-1) being without significant effect in the assay (Table 2 ). In contrast, mono-labelling with sCy5 as in 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 observed, likely reflecting some co-internalisation of Y 4 R ligand complexes from the plasma membrane following receptor activation. The presence of increasing concentrations of PP competed for the binding of (S,S)-14 or (R,R)-14.
To confirm the utility of (R,R)-14 in competition binding experiments, the fluorescence spectrum in physiological buffers was determined and found the lambda max to be the same as that of the underivatised sCy5-NHS dye (absorption max 656 nm, emission max 665 nm) with a relative quantum yield of 31% (see Supporting Information). We then used (R,R)-14 to label cells with 100 nM (R,R)-14, and determined the PP pIC 50 was 8.36±0.09 (IC 50 = 4.31 nM, n = 3), consistent with the IC 50 obtained using 17 (see Table 2 ).
The collected assay data from these studies raise interesting questions regarding the molecular mechanism governing the high potency of peptide (R,R)-1 as compared to other analogues, and therefore how dimeric analogues impart enhanced affinity generally. Set against recent studies of the Y 4 R-hPP interaction, 42 the simplest model is that the "first arm"
of the dimer binds the receptor in the canonical fashion while the "second arm" contributes to 
Peptide synthesis
The purity of all reported peptides are ≥ 95% according to the HPLC chromatographs produced by the ESI-MS method described above.
General synthesis
Linear peptide chains were synthesised on Rink amide resin or 2-chlorotrityl chloride resin (sequence dependent) using a 3-channel serial automated peptide synthesiser ("PS3", Protein Technologies Inc.), which adopted standard Fmoc-based solid phase synthesis strategy. The (R,R) diastereomer of I was prepared in the same fashion as the (S,S)-diastereomer, but on 0.05 mmol scale, and using (R,R)-5 yielding a fluffy white sold (13.4 mg Alternatively, peptide (R,R)-9 (16 mg) (see below) was dissolved in EtOAc (10 ml) then cycled through an H-Cube™ incorporating a 10% Pd/C cartridge at 50˚C at 1.5 ml/min under H 2 (50 psi). After 1h the solvent was removed in vacuo and the residue was purified by HPLC to yield a white fluffy solid (9.2 mg). 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 A mixture of Fmoc-Tyr-OMe, 10 (2 eq.) and DIPEA (6 eq.) in DCM (5 ml) was added to 2-chlorotrityl resin and agitated overnight. The resin was filtered, washed with DCM×3, MeOH×1 and Et 2 O×1, and dried in vacuo. The derivatised resin was subject to standard solid phase synthesis as described above and treated with (2S,7S)-5 as described for (S,S)-1 above.
After cleavage and purification, the peptide was lyophilized to yield a white fluffy solid (40.5 mg 
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